NCT07752563

Brief Summary

The goal of this study is to learn whether NeuroEyeCoach, a computer-based eye movement training programme, can help stroke survivors with visual field loss. The study will also assess whether a larger clinical trial is feasible. The main questions it aims to answer are:

  • Can stroke survivors be successfully recruited, randomised and followed up in a larger trial?
  • Is NeuroEyeCoach acceptable and practical to use?
  • Is there early evidence that NeuroEyeCoach improves vision-related functioning and wellbeing? Researchers will compare NeuroEyeCoach plus usual care with usual care alone. Participants will:
  • Be randomly assigned to receive NeuroEyeCoach plus usual care or usual care alone
  • Complete six weeks of training if allocated to NeuroEyeCoach
  • Complete questionnaires and tests of vision, daily activities, quality of life, confidence and wellbeing
  • Take part in follow-up assessments over six months This pilot trial will include 60 stroke survivors living with visual field loss after stroke. Findings will be used to inform the design of a larger study.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P50-P75 for not_applicable stroke

Timeline
10mo left

Started Oct 2026

Shorter than P25 for not_applicable stroke

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 3, 2025

Completed
8 months until next milestone

First Posted

Study publicly available on registry

August 7, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

October 1, 2026

Expected
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2027

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2027

Last Updated

August 7, 2026

Status Verified

August 1, 2026

Enrollment Period

10 months

First QC Date

December 3, 2025

Last Update Submit

August 3, 2026

Conditions

Keywords

visual field lossrehabilitationpilot RCTprocess evaluation

Outcome Measures

Primary Outcomes (1)

  • Recruitment rate

    Rate of recruitment to the trial

    through study completion, estimated at 15 months

Secondary Outcomes (13)

  • Retention Rate

    through study completion, estimated at 15 months

  • Screening and eligibility rate

    Active screening period

  • Outcome measure completion rate

    over data collection period

  • intervention adherence

    6 weeks

  • Adverse events

    up to 6 weeks

  • +8 more secondary outcomes

Study Arms (2)

Eye movement training + usual care

EXPERIMENTAL

Usual post-stroke care, plus eye movement training (VISIOcoach)

Device: NeuroEyeCoach eye movement trainingOther: Usual Care

usual care

OTHER

Usual post-stroke care

Other: Usual Care

Interventions

computer based eye movement training for visual field loss in stroke

Eye movement training + usual care

Usual post-stroke care

Eye movement training + usual careusual care

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • adult (\>18 years)
  • stroke survivor
  • stroke-related homonymous VFL (minimum quadrantanopia)
  • sufficient language, cognitive, and upper limb ability to participate in trial activities.

You may not qualify if:

  • pre-existing (ie pre-stroke) registration as sight impaired (partially sighted) or severely sight impaired (blind)
  • history of seizure disorders, especially those of a photosensitive nature

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Central Study Contacts

Christine Hazelton, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 3, 2025

First Posted

August 7, 2026

Study Start (Estimated)

October 1, 2026

Primary Completion (Estimated)

July 31, 2027

Study Completion (Estimated)

July 31, 2027

Last Updated

August 7, 2026

Record last verified: 2026-08